tiprankstipranks
Trending News
More News >
Castle Biosciences (CSTL)
NASDAQ:CSTL
US Market
Advertisement

Castle Biosciences (CSTL) Earnings Dates, Call Summary & Reports

Compare
442 Followers

Earnings Data

Report Date
Nov 10, 2025
After Close (Confirmed)
Period Ending
2025 (Q3)
Consensus EPS Forecast
-0.53
Last Year’s EPS
0.08
Same Quarter Last Year
Based on 7 Analysts Ratings

Earnings Call Summary

Q2 2025
Earnings Call Date:Aug 04, 2025|
% Change Since: 29.37%|
Earnings Call Sentiment|Neutral
Castle Biosciences demonstrated strong growth in test volumes and revenue, particularly with the TissueCypher and DecisionDx-Melanoma tests. However, reimbursement challenges with the DecisionDx-SCC test and increased operating expenses impacted financial results. Despite these challenges, the company raised its revenue guidance and maintains a strong financial position.
Company Guidance -
Q3 2025
During the Castle Biosciences Q2 2025 earnings call, the company provided guidance on several key financial metrics and strategic priorities. Castle reported a revenue of $86.2 million for Q2, with a total test report volume of 26,574, marking a 33% year-over-year growth for core revenue drivers. The company concluded the quarter with $275.9 million in cash, cash equivalents, and marketable securities, supporting ongoing investment in growth initiatives. Castle reiterated its expectations for high single-digit volume growth for DecisionDx-Melanoma for the full year 2025. For 2025, the total revenue guidance was raised to $310 million to $320 million, reflecting a positive outlook despite the DecisionDx-SCC reimbursement challenges. Adjusted gross margin was reported at 79.5%, with expectations of maintaining low to mid-70s in the future. The company is focusing on strategic M&A opportunities and pipeline developments, including advancements in dermatologic and gastrointestinal testing, with ongoing projects such as a collaboration with SciBase and the development of a new atopic dermatitis test.
Strong Revenue and Test Volume Growth
Castle Biosciences reported Q2 2025 revenue of $86.2 million with a 33% year-over-year increase in core revenue driver test volumes. The company ended the quarter with $275.9 million in cash, cash equivalents, and marketable securities.
TissueCypher Test Performance
The TissueCypher test showed a 92% year-over-year growth with 9,170 reports in Q2 2025, up from 4,782 in Q2 2024, reflecting strong momentum in the gastroenterology franchise.
DecisionDx-Melanoma Test Success
Castle Biosciences delivered 9,981 DecisionDx-Melanoma test reports in Q2 2025, a sequential increase of 16% from Q1 2025 and a 4% year-over-year increase, marking the largest sequential increase since the IPO in 2019.
Collaborations and Pipeline Developments
Castle Biosciences entered a collaboration with SciBase to develop a diagnostic test for atopic dermatitis, with plans to launch by the end of 2025. A new genomic signature for predicting treatment response in atopic dermatitis has also been identified.
Financial Performance and Guidance
The company raised its 2025 revenue guidance to $310 million to $320 million, up from the previous range of $287 million to $297 million, reflecting strong performance and growth expectations.

Castle Biosciences (CSTL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

CSTL Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Nov 10, 2025
2025 (Q3)
-0.53 / -
0.08
Aug 04, 2025
2025 (Q2)
-0.53 / 0.15
0.31-51.61% (-0.16)
May 05, 2025
2025 (Q1)
-0.07 / -0.90
-0.09-900.00% (-0.81)
Feb 27, 2025
2024 (Q4)
0.05 / 0.32
-0.1420.00% (+0.42)
Nov 04, 2024
2024 (Q3)
>-0.01 / 0.08
-0.26130.77% (+0.34)
Aug 05, 2024
2024 (Q2)
-0.27 / 0.31
-0.7144.29% (+1.01)
May 02, 2024
2024 (Q1)
-0.33 / -0.09
-1.191.82% (+1.01)
Feb 28, 2024
2023 (Q4)
-0.56 / -0.10
-0.7887.18% (+0.68)
Nov 02, 2023
2023 (Q3)
-0.76 / -0.26
-0.7766.23% (+0.51)
Aug 02, 2023
2023 (Q2)
-0.92 / -0.70
-0.06-1066.67% (-0.64)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

CSTL Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Aug 04, 2025
$15.32$20.35+32.83%
May 05, 2025
$18.75$16.62-11.36%
Feb 27, 2025
$25.28$21.68-14.24%
Nov 04, 2024
$33.64$31.15-7.40%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Castle Biosciences (CSTL) report earnings?
Castle Biosciences (CSTL) is schdueled to report earning on Nov 10, 2025, After Close (Confirmed).
    What is Castle Biosciences (CSTL) earnings time?
    Castle Biosciences (CSTL) earnings time is at Nov 10, 2025, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is CSTL EPS forecast?
          CSTL EPS forecast for the fiscal quarter 2025 (Q3) is -0.53.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis